Nasal administration of myelin basic protein prevents relapsing experimental autoimmune encephalomyelitis in DA rats by activating regulatory cells expressing IL-4 and TGF-β mRNA

Journal of Neuroimmunology

Volumn 80, Issue 1-2, 1997, Pages 65-75

  Bai, Xue Feng ^a   Shi, Fu Dong ^a   Xiao, Bao Guo ^a   Li, Hu Lun ^a   Van Der Meide, Peter H ^b   Link, Hans ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b BIOMEDICAL PRIMATE RESEARCH CENTRE   (Netherlands)

Author keywords

Cytokine; Experimental autoimmune encephalomyelitis; IL 4; Mucosal tolerance; TGF

Indexed keywords

FREUND ADJUVANT; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G2B; INTERLEUKIN 4; MESSENGER RNA; MYELIN BASIC PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; HELPER CELL; IMMUNIZATION; IMMUNOLOGICAL TOLERANCE; INTRANASAL DRUG ADMINISTRATION; MULTIPLE SCLEROSIS; NONHUMAN; PRIORITY JOURNAL; RAT; SPLEEN CELL;

ADMINISTRATION, INTRANASAL; ANIMALS; ANTIBODY SPECIFICITY; CATTLE; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; EPITOPES; IMMUNE TOLERANCE; IMMUNOGLOBULIN G; IMMUNOGLOBULIN ISOTYPES; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN-4; LYMPHOCYTE ACTIVATION; MYELIN BASIC PROTEINS; RATS; RATS, INBRED STRAINS; RECURRENCE; RNA, MESSENGER; SPINAL CORD; SPLEEN; TH1 CELLS; TRANSFORMING GROWTH FACTOR BETA;

EID: 0031469731     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-5728(97)00133-1     Document Type: Article

References (41)

1. Alastair J., Bradley J.A. Interleukin-12 induces interferon-γ-dependent switching of IgG alloantibody subclass. Eur. J. Immunol. 26:1996;1217-1221.
2. Al-Sabbagh A., Miller A., Santos L.M.B., Weiner H.L. Antigen-driven tissue-specific suppression following oral tolerance: Orally administered myelin basic protein suppresses proteolipid protein-induced experimental autoimmune encephalomyelitis in the SJL mouse. Eur. J. Immunol. 24:1994;2104-2109.
3. Ben-Nun A., Wekerle H., Cohen I.R. The rapid isolation of clonable antigen-specific lines capable of mediating autoimmune encephalomyelitis. Eur. J. Immunol. 11:1981;195-199.
4. Brocke S., Gijbels K., Allegretta M., Ferber I., Piercy C., Blankenstein T., Martin R., Utz U., Karin N., Mitchell D., Veromaa T., Waisman A., Gaur A., Conlon P., Ling N., Fairchild P.J., Wraith D.C., O'Garra A., Fathman C.G., Steinman L. Treatment of experimental encephalomyelitis with a peptide analogue of myelin basic protein. Nature. 379:1996;343-346.
5. Cannella B., Raine C.C. The adhesion molecule and cytokine profile of multiple sclerosis lesions. Ann. Neurol. 37:1995;424-435.
6. Chen Y., Inobe J.-I., Kuchroo V.K., Baron J.L., Janeway C.A. Jr., Weiner H.L. Oral tolerance in myelin basic protein T cell receptor transgenic mice: Suppression of autoimmune encephalomyelitis and dose-dependent induction of regulatory cells. Proc. Natl. Acad. Sci. USA. 93:1996;388-391.
7. Daniel D., Wegmann D.R. Protection of nonobese diabetic mice diabetes by intranasal or subcutaneous administration of insulin peptide B-(9-23). Proc. Natl. Acad. Sci. USA. 93:1996;956-960.
8. Deibler G.E., Martensson R.E., Kies M.W. Large scale preparation of myelin basic protein from central nervous tissue of several mammalian species. Prep. Biochem. 2:1972;139-164.
9. Dick A.D., Cheng Y.F., McKinnon A., Liversidge J., Forrester J.V. Nasal administration of retinal antigens suppresses the inflammatory response in experimental allergic uveoretinitis, A preliminary report of intranasal induction of tolerance with retinal antigens. Br. J. Ophthalmol. 77:1993;171-175.
10. Dick A.D., Cheng Y.F., Liversidge J., Forrester J.V. Intranasal administration of retinal antigens suppresses retinal antigen-induced experimental autoimmune uveoretinitis. Immunol. 82:1994;625-631.
11. Fairchild P.J., Thorpe C.J., Traver P.J., Wraith D.C. Modulation of the immune response with T-cell epitopes: The ultimate goal for specific immunotherapy of autoimmune disease. Immunol. 81:1994;487-496.
12. Friedman A., Weiner H.L. Induction of anergy or active suppression following oral tolerance is determined by antigen dosage. Proc. Natl. Acad. Sci. USA. 91:1994;6688-6692.
13. + Th1 but not Th2 cytokine responses. Int. Immunol. 6:1994;721-730.
14. Khoury S.J., Hancock W.W., Weiner H.L. Oral tolerance to myelin basic protein and natural recovery from experimental autoimmune encephalomyelitis are associated with down-regulation of inflammatory cytokines and differential upregulation of transforming growth factor β, interleukin 4, and prostaglandin E expression in the brain. J. Exp. Med. 176:1992;1355-1364.
15. Lehmann P.V., Forsthuber T., Miller A., Sercarz E.E. Spreading of T-cell autoimmunity to cryptic determinants of an autoantigen. Nature. 358:1992;155-157.
16. Lindström J., Einarson B., Tzartos S. Production and assay of antibodies to acetylcholine receptors. Methods Enzymol. 74:1981;432-460.
17. Link H., Olsson O., Sun J.-B., Wang W.-Z., Andersson G., Ekre H.-P., Brenner T., Abramsky O., Olsson T. Acetylcholine receptor-reactive T and B cells in myasthenia gravis and controls. J. Clin. Invest. 87:1991;2191-2196.
18. Lorentzen J.C., Issazadeh S., Storch M., Mustafa M.I., Lassman H., Linington C., Klareskog L., Olsson T. Protracted, relapsing and demyelinating experimental autoimmune encephalomyelitis in DA rats immunized with syngeneic spinal cord and in complete Freund's adjuvant. J. Neuroimmunol. 63:1995;193-205.
19. Ma C.G., Zhang G.X., Xiao B.G., Link J., Olsson T., Link H. Suppression of experimental autoimmune myathenia gravis by nasal administration of acetylcholine receptor. J. Neuroimmunol. 58:1995;51-60.
20. Ma C.G., Zhang G.X., Xiao B.G., Wang Z.Y., Link J., Olsson T., Link H. Mucosal tolerance to experimental autoimmune myasthenia gravis is associated with down-regulation of AChR-specific IFN-γ-expressing Th1-like cells and up-regulation of TGF-β mRNA in mononuclear cells. Ann. N.Y. Acad. Sci. 778:1996;273-287.
21. + T cell-dependent immune deviation resulting in selective suppression of immunoglobulin E production. J. Exp. Med. 178:1993;889-899.
22. Metzler B., Wraith D.C. Inhibition of experimental autoimmune encephalomyelitis by inhalation but not oral administration of the encephalitogenic peptide: Inhibition of MHC binding affinity. Int. Immunol. 5:1993;1159-1165.
23. Metzler B., Wraith D.C. Mucosal tolerance in a murine model of experimental autoimmune encephalomyelitis. Ann. N.Y. Acad. Sci. 778:1996;228-243.
24. Meyer A.L., Benson J.M., Gienapp I.E., Cox K.L., Whitacre C.C. Suppression of murine chronic relapsing experimental autoimmune encephalomyelitis by the oral administration of myelin basic protein. J. Immunol. 157:1996;4230-4238.
25. Miller A., Lider O., Weiner H.L. Antigen-driven bystander suppression after oral administration of antigens. J. Exp. Med. 174:1991;791-798.
26. Miller A., AI-Sabbagh A., Santos L.M.B., Das M.P., Weiner H.L. Epitopes of myelin basic protein that trigger TGF-β release after oral tolerization are distinct from encephalitogenic epitopes and mediate epitope-driven bystander suppression. J. Immunol. 151:1993;7307-7315.
27. Müssener Å., Lorentzen J.C., Kleinau S., Klareskog L. Altered Th1/Th2 balance associated with non-major histocompatibility complex genes in collagen-induced arthritis in resistant and non-resistant rat strains. Eur. J. Immunol. 27:1997;695-699.
28. Peterson J.D., Karpus W.J., Clatch R.J., Miller S.D. Split tolerance of Th1 and Th2 cells in tolerance to Theiler's murine encephalomyelitis virus. Eur. J. Immunol. 23:1993;46-55.
29. Racke M.K., Bonomo A., Scott D.E., Cannella B., Levine A., Raine C.S., Shevach E.M., Rocken M. Cytokine-induced immune deviation as a therapy for inflammatory autoimmune disease. J. Exp. Med. 180:1994;1961-1966.
30. Raine C.S. Multiple sclerosis: TNF revisited, with promise. Nature Med. 1:1995;211-214.
31. Stepaniak J.A., Gould K.E., Sun D., Swanborg R.H. A comparative study of experimental autoimmune encephalomyelitis in Lewis and DA rats. J. Immunol. 155:1995;2762-2769.
32. St. Louis J., Chan E.L., Singh B., Strejan G.H. Suppression of experimental allergic encephalomyelitis in the Lewis rat, by administration of an acylated synthetic peptide of myelin basic protein. J. Neuroimmunol. 73:1997;90-100.
33. Van der Meide P.H., Dubbeld M., Vijverberg K., Kos T., Schellekens H. The purification of rat gamma interferon by use of two monoclonal antibodies. J. Gen. Virol. 67:1986;1059-1071.
34. Vassalli P. The pathophysiology of tumor necrosis factors. Ann. Rev. Immunol. 10:1992;411-452.
35. Waisman A., Ruiz P.J., Hirschberg D.L., Gelman A., Oksenberg J.R., Brocke S., Mor F., Cohen I.R., Steinman L. Suppressive vaccination with DNA encoding a variable region gene of the T-cell receptor prevents autoimmune encephalomyelitis and activates Th2 immunity. Nature Med. 2:1996;899-905.
36. Weiner H.L., Mackin G.A., Matsui M., Orav E.J., Khoury S.J., Dawson D.M., Hafler D.A. Double-blind pilot trial of oral tolerization with myelin antigens in multiple sclerosis. Science. 259:1993;1321-1324.
37. Weiner H.L., Friedman A., Miller A., Khoury S.J., Al-Sabbagh A., Santos L., Sayegh M., Nussenblatt R.B., Trentham D.E., Hafler D.A. Oral tolerance: Immunologic mechanisms and treatment of animal and human organ-specific autoimmune diseases by oral administration of autoantigens. Annu. Rev. Immunol. 12:1994;809-837.
38. Whitacre C.C., Gienapp I.E., Meyer A., Cox K.L., Javed N. k Treatment of autoimmune disease by oral tolerance to autoantigens. Clin. Immunol. Immunopathol. 80:1996;S31-S39.
39. Wraith D.C. Antigen-specific immunotherapy of autoimmune disease: A commentary. Clin. Exp. Immunol. 103:1996;349-352.
40. Xiao B.G., Bai X.F., Zhang G.X., Höjeberg B., Link H. Shift from anti- to proinflammatory cytokine profiles in microglia through LPS- or IFN-γ-mediated pathways. NeuroReport. 7:1996;1893-1898.
41. Zhang Z.J., Lee C.S.Y., Lider O., Weiner H.L. Suppression of adjuvant arthritis in Lewis rats by oral administration of type II collagen. J. Immunol. 145:1990;2489-2493.